DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublicaciones en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (12)
2023
-
Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Clinical Cancer Research, Vol. 29, Núm. 21
-
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): “Real World” Experience
Clinical Genitourinary Cancer, Vol. 21, Núm. 5, pp. 584-593
2022
-
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 20, Núm. 5, pp. e440-e452
-
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer
BJU International, Vol. 130, Núm. 5, pp. 592-603
-
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 20, Núm. 6, pp. 558-567
-
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
Nature communications, Vol. 13, Núm. 1, pp. 1878
-
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Clinical Cancer Research, Vol. 28, Núm. 10, pp. 2050-2060
-
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin
Clinical Genitourinary Cancer, Vol. 20, Núm. 2, pp. 165-175
2021
-
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
European urology oncology, Vol. 4, Núm. 3, pp. 464-472
-
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
BJU International, Vol. 128, Núm. 2, pp. 196-205